PeerView Oncology

 

PeerView Oncology
Avatar

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or Combination Therapy & What Is the Next Step in Case of Liver Mets?

By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
11 views
May 28, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lung
17:03
PeerView Oncology

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung A…

Feat. E. Garon, J. Heymach
15:20
PeerView Oncology

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multi…

Feat. B. Stiles
15:18
PeerView Oncology

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in C…

Feat. S. Patel
02:22
PeerView Oncology

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or C…

Feat. S. Patel, M. Ahluwalia, K. Beal
05:24
PeerView Oncology

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutat…

Feat. S. Patel, M. Ahluwalia, K. Beal
17:21
PeerView Oncology

Management of EGFR-Mutant Lung Cancer With Central Nervous System Me…

Feat. S. Patel, M. Ahluwalia, K. Beal
04:37
PeerView Oncology

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Me…

Feat. S. Patel, M. Ahluwalia, K. Beal